» Articles » PMID: 14504467

SUMO and Transcriptional Repression: Dynamic Interactions Between the MAP Kinase and SUMO Pathways

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2003 Sep 25
PMID 14504467
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

SUMO modification of proteins is being increasingly linked with transcriptional repression. We recently demonstrated that SUMO modification also downregulates the transcriptional activity of the ETS-domain transcription factor Elk-1. However, as Elk-1 becomes activated through MAP kinase-mediated phosphorylation, the SUMO modification is lost, providing an elegant molecular switch that promotes the loss of repressive activities at the same time as permitting the recruitment of coactivator proteins. However, the mechanism by which SUMO promotes transcriptional repression remains enigmatic.

Citing Articles

Crosstalk between SUMOylation and other post-translational modifications in breast cancer.

Wei B, Yang F, Yu L, Qiu C Cell Mol Biol Lett. 2024; 29(1):107.

PMID: 39127633 PMC: 11316377. DOI: 10.1186/s11658-024-00624-3.


Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination.

Zhang J, Wang H, Fan Y, Yu Z, You G Pharmacol Ther. 2020; 217:107647.

PMID: 32758646 PMC: 7770002. DOI: 10.1016/j.pharmthera.2020.107647.


Insulin-like growth factor 1 modulates the phosphorylation, expression, and activity of organic anion transporter 3 through protein kinase A signaling pathway.

Zhang J, Yu Z, You G Acta Pharm Sin B. 2020; 10(1):186-194.

PMID: 31993315 PMC: 6977015. DOI: 10.1016/j.apsb.2019.05.005.


Activation of Protein Kinase A Stimulates SUMOylation, Expression, and Transport Activity of Organic Anion Transporter 3.

Wang H, Zhang J, You G AAPS J. 2019; 21(2):30.

PMID: 30761470 PMC: 6647857. DOI: 10.1208/s12248-019-0303-4.


HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs).

Paget S, Dubuissez M, Dehennaut V, Nassour J, Harmon B, Spruyt N Oncotarget. 2016; 8(2):2916-2935.

PMID: 27935866 PMC: 5356852. DOI: 10.18632/oncotarget.13807.